| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c1c1bc53b6d1b93c460c22fd4081d92d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate |
2004-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2ec679f67cb83dfed5031bb83ed7939 |
| publicationDate |
2007-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007202078-A1 |
| titleOfInvention |
Method Of Treating Viral Infections |
| abstract |
A method of pharmaceutical therapy includes co-administering: (A) interferon or derivative thereof with a low dose of B ribavirin ≦400 mg/day or ≦6 mg/kg/day), or related compound, where (B) provides a clinically effective blood level in portal circulation but less than clinically effective blood level in peripheral circulation, thereby providing a systemic effect of interferon throughout the body but a selective effect of ribavirin in the liver. The method also provides for co-administration of (A) with a high dose of (B) (preferably 400-800 mg/day) where (B) is administered as a slow-release formulation to provide a sustained virologic response and reduced side effects. The method also provides for co-adminstering (C) antioxidant or other membrane protective agent with both interferon and ribavirin such that the hepatoprotective activity of (C) complements the virucidal effect of interferon and ribavirin. (C) may be administered as a systemic or low-dose, slow-release, liver-selective formulation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012066581-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008161311-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010068182-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011014882-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8822496-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8399484-B2 |
| priorityDate |
2003-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |